Researchers have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they ...

When you can’t take down the kingpin, go after his accomplices. This strategy may work for cancer as well, according to scientists at Fred Hutch Cancer Center and Memorial Sloan Kettering Cancer ...

National Institutes of Health (NIH) scientists and collaborators say they have discovered a new way in which RAS genes, commonly mutated in cancer, may drive tumor growth beyond their well-known role ...

The team showed that removing this protective system could stop cancer in its tracks. When they knocked out the P2Y2 receptor in drug-resistant cancer cells, it led to an almost complete loss of the ...

Schematic illustrating the effects of p53C and M237I in driving the conversion of p63C and p73C droplets into amyloid aggregates at physiologically relevant temperatures. Heparin prevents the ...

Researchers at the Center for Algorithmic and Robotized Synthesis within the Institute for Basic Science have taken a significant step forward in understanding the stability of proteins by leveraging ...

Vepdegestrant becomes the first FDA-approved heterobifunctional protein degrader (PROTAC) in breast cancer, targeting ER ...

Researchers from Elpiscience Biopharmaceuticals Inc. discussed the discovery and preclinical characterization of a novel NKG2A antibody-IL-2 mutant fusion protein – ES-015.129 – being developed as ...

Researchers showed that small engineered proteins can restore the function of mutated p53 by stabilizing its structure. The ...

Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programsPresentations reinforce potential of degraders ...